Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CCKBR | P32239 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6154117 | 1.00 | LMNA (0.55) | LMNASMN1; SMN2CYP1A2HTTALDH1A1 | |
| SCHEMBL633304 | 1.00 | LMNA (0.55) | LMNASMN1; SMN2CYP1A2HTTALDH1A1 | |
| SCHEMBL13897189 | 0.88 | CYP1A2 (0.50) | LMNASMN1; SMN2CYP1A2HTTALDH1A1 | |
| SCHEMBL5542852 | 0.85 | SMN1; SMN2 (0.47) | SMN1; SMN2CYP1A2ALDH1A1GAATSHR | |
| SCHEMBL5546401 | 0.85 | POLB (0.47) | LMNASMN1; SMN2CYP1A2ALDH1A1CCKBR | |
| SCHEMBL591373 | 0.85 | LMNA (0.60) | LMNASMN1; SMN2HTTALDH1A1GAA | |
| SCHEMBL30772550 | 0.84 | CYP1A2 (0.52) | LMNASMN1; SMN2CYP1A2HTTALDH1A1 | |
| SCHEMBL31310017 | 0.84 | LMNA (0.51) | LMNASMN1; SMN2CYP1A2HTTALDH1A1 | |
| SCHEMBL11537938 | 0.84 | CYP1A2 (0.48) | LMNASMN1; SMN2CYP1A2HTTALDH1A1 | |
| SCHEMBL6154554 | 0.83 | SMN1; SMN2 (0.47) | LMNASMN1; SMN2CYP1A2HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024200838-A1 | NEW ODILORHABDINS ANALOGUES AS ANTIBIOTICS AGAINST MULTI-RESISTANT BACTERIA | NOSOPHARM (FR) | 2024-10-03 | — | — | WO | disclosed |
| EP-3442949-B1 | CONTRAST AGENTS | BRACCO IMAGING SPA (IT) | 2022-06-08 | — | — | EP | disclosed |
| US-11007283-B2 | Contrast agents | BRACCO IMAGING S.P.A. (IT) | 2021-05-18 | — | — | US | disclosed |
| US-20190167819-A1 | CONTRAST AGENTS | BRACCO IMAGING S.P.A. (IT) | 2019-06-06 | — | — | US | disclosed |
| EP-2531221-B1 | POLYANIONIC MULTIVALENT MACROMOLECULES FOR INTRACELLULAR TARGETING OF PROLIFERATION AND PROTEIN SYNTHESIS | IC DISCOVERY GMBH (DE) | 2019-03-13 | — | — | EP | disclosed |
| WO-2017178301-A1 | CONTRAST AGENTS | BRACCO IMAGING SPA (IT) | 2017-10-19 | — | — | WO | disclosed |
| WO-2017098038-A1 | CONTRAST AGENTS | BRACCO IMAGING SPA (IT) | 2017-06-15 | — | — | WO | disclosed |
| EP-2905283-B1 | Oxazolidinone antibiotics | ACTELION PHARMACEUTICALS LTD (CH) | 2016-12-14 | — | — | EP | disclosed |
| US-9505750-B2 | 5-aminocyclylmethyl-oxazolidin-2-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-11-29 | — | — | US | disclosed |
| EP-2144910-B1 | OXAZOLIDINONE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-10-28 | — | — | EP | disclosed |
| US-20070155728-A1 | Substituted Heterocyclic Compounds | PALLE VENKATA | 2007-07-05 | — | — | US | disclosed |
| US-7205303-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205303-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1339701-B1 | HETEROARYL ALKYL PIPERAZINE DERIVATIVES AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS INC (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| US-20050215801-A1 | Process for preparation of optically active 1-substituted amino-2,3-epoxypropanes, intermediates for synthesis thereof and process for preparation of the intermediates | KANEKA CORPORATION (JP) | 2005-09-29 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1553093-A1 | PROCESS FOR PREPARATION OF OPTICALLY ACTIVE 1-SUBSTITUTED AMINO-2,3-EPOXYPROPANES, INTERMEDIATES FOR THE SYNTHESIS THEREOF AND PROCESS FOR PREPARATION OF THE INTERMEDIATES | KANEKA CORPORATION (JP) | 2005-07-13 | — | — | EP | disclosed |
| EP-1071654-B1 | A PROCESS FOR PREPARING CHIRAL (S)-2,3-DISUBSTITUTED-1-PROPYLAMINE DERIVATIVES | SAMSUNG FINE CHEMICALS CO LTD (KR) | 2003-10-22 | — | — | EP | disclosed |
| US-6417403-B1 | AMINATION OF 3,4-DISUBSTITUTED-1-BUTANECARBONYL DERIVATIVE THROUGH CURTIUS OR HOFMAN REARRANGEMENT; SALT FORMATION, CARBAMYLATION | SAMSUNG FINE CHEMICALS CO., LTD. (KR) | 2002-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | LMNA 4152/4885SMN1; SMN2 3985/4885CYP1A2 659/4885 |
| US-11007283-B2 | Contrast agents | PHOSPHO1, ITPA, PPIP5K2 | LMNA 2726/4885SMN1; SMN2 1789/4885CYP1A2 4864/4885 |
| US-20190167819-A1 | CONTRAST AGENTS | PHOSPHO1, ITPA, PPIP5K2 | LMNA 2726/4885SMN1; SMN2 1789/4885CYP1A2 4864/4885 |
| US-20050215801-A1 | Process for preparation of optically active 1-substituted amino-2,3-epoxypropanes, intermediates for synthesis thereof and process for preparation of the intermediates | OXER1, RCC2, CBR3 | LMNA 3686/4885SMN1; SMN2 4620/4885CYP1A2 62/4885 |
| US-20070155728-A1 | Substituted Heterocyclic Compounds | KCNH1, SDHA, COQ8A | LMNA 2300/4885SMN1; SMN2 2336/4885CYP1A2 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.